Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia
Summary Background: Co‐administration of niacin with statin offers the potential for additional lipid management and cardiovascular risk reduction. However, niacin is underutilised because of the side effects of flushing, mediated primarily by prostaglandin D2 (PGD2). A combination tablet containin...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2010-05, Vol.64 (6), p.727-738 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 738 |
|---|---|
| container_issue | 6 |
| container_start_page | 727 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 64 |
| creator | Shah, S. Ceska, R. Gil-Extremera, B. Paolini, J. F. Giezek, H. Vandormael, K. Mao, A. McCrary Sisk, C. Maccubbin, D. |
| description | Summary
Background: Co‐administration of niacin with statin offers the potential for additional lipid management and cardiovascular risk reduction. However, niacin is underutilised because of the side effects of flushing, mediated primarily by prostaglandin D2 (PGD2). A combination tablet containing extended‐release niacin and laropiprant (ERN/LRPT), a PGD2 receptor (DP1) antagonist, offers improved tolerability. This study assessed the efficacy and safety of ERN/LRPT added to statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia who were not at their National Cholesterol Education Program Adult Treatment Panel III low‐density lipoprotein cholesterol (LDL‐C) goal based on their coronary heart disease risk category (high, moderate or low).
Methods: After a 2‐ to 6‐week run‐in statin (simvastatin 10 or 20 mg or atorvastatin 10 mg) period, 1216 patients were randomised equally to one of two treatment groups in a double‐blind fashion: group 1 received ERN/LRPT (1 g) plus the run‐in statin dose and advanced to ERN/LRPT (2 g) after 4 weeks for an additional 8 weeks, with no adjustments to the run‐in statin dose; group 2 received simvastatin or atorvastatin at twice their run‐in statin dose and remained on this stable dose for 12 weeks.
Results: ERN/LRPT added to statin (pooled across statin and statin dose) significantly improved key lipid parameters vs. the doubled statin dose (pooled): the between‐treatment group difference in least squares mean per cent change [95% confidence interval (CI)] from baseline to week 12 in LDL‐C (primary end‐point) was −4.5% (−7.7, −1.3) and in high‐density lipoprotein cholesterol (HDL‐C) was 15.6% (13.4, 17.9) and in median per cent change for triglyceride (TG) was −15.4% (−19.2, −11.7). Treatment‐related adverse experiences (AEs) related to flushing, pruritis, rash, gastrointestinal upset and elevations in liver transaminases and fasting serum glucose occurred more frequently with ERN/LRPT added to statin vs. statin dose doubled.
Conclusions: The addition of ERN/LRPT to ongoing statin treatment produced significantly improved lipid‐modifying benefits on LDL‐C, HDL‐C and TG and all other lipid parameters compared with doubling the statin dose in patients with primary hypercholesterolaemia or mixed dyslipidaemia. The types of AEs that occurred at a greater frequency in the ERN/LRPT group were those typically associated with niacin. |
| doi_str_mv | 10.1111/j.1742-1241.2010.02370.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733137426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733137426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4870-3c2a4de79c616b0bc80ac73100627a228af4908c3e2eb8bc9c0b6722d261b08e3</originalsourceid><addsrcrecordid>eNqNUdtu1DAQjRCIlsIvIL8gnpL6ktjOCxJatUtRBRUq4tFynAnrxblgJzT5Jz4Sp7ssr1iWPJ45c-ZykgQRnJF4LvcZETlNCc1JRnH0YsoEzuYnyfkp8DTajMu0wIycJS9C2GNMi0Li58kZxQWRZS7Pk99XTWONNgvSXY2CbmBcUN8gmEfoaqhTDw50ANRZbWx36bTvBzt43Y1ocFNAYdSj7dCvkKG6nypnu-9o3EH8xKRIdIzHO0QDujGgBzvu0OBtq_2CdssA3ux6B2EE3zsNrdWo96i1M9SoXoKzg60f3S-TZ412AV4d34vk6_XV_eZDevt5e7N5f5uaXAqcMkN1XoMoDSe8wpWRWBvBCMacCk2p1E1eYmkYUKhkZUqDKy4orSknFZbALpK3B97B9z-n2JhqbTDgnO6gn4ISjBEW98wjUh6QxvcheGjUcS5FsFqlUnu1KqJWRdQqlXqUSs0x9fWxyFS1UJ8S_2oTAW-OAB2Mdk3cubHhH45yWRIiIu7dAfdgHSz_3YC6-bi5W81IkB4IbJRgPhFo_0NxwUShvn3aKobvt_zLHY_D_wF_J8KC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733137426</pqid></control><display><type>article</type><title>Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Shah, S. ; Ceska, R. ; Gil-Extremera, B. ; Paolini, J. F. ; Giezek, H. ; Vandormael, K. ; Mao, A. ; McCrary Sisk, C. ; Maccubbin, D.</creator><creatorcontrib>Shah, S. ; Ceska, R. ; Gil-Extremera, B. ; Paolini, J. F. ; Giezek, H. ; Vandormael, K. ; Mao, A. ; McCrary Sisk, C. ; Maccubbin, D.</creatorcontrib><description>Summary
Background: Co‐administration of niacin with statin offers the potential for additional lipid management and cardiovascular risk reduction. However, niacin is underutilised because of the side effects of flushing, mediated primarily by prostaglandin D2 (PGD2). A combination tablet containing extended‐release niacin and laropiprant (ERN/LRPT), a PGD2 receptor (DP1) antagonist, offers improved tolerability. This study assessed the efficacy and safety of ERN/LRPT added to statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia who were not at their National Cholesterol Education Program Adult Treatment Panel III low‐density lipoprotein cholesterol (LDL‐C) goal based on their coronary heart disease risk category (high, moderate or low).
Methods: After a 2‐ to 6‐week run‐in statin (simvastatin 10 or 20 mg or atorvastatin 10 mg) period, 1216 patients were randomised equally to one of two treatment groups in a double‐blind fashion: group 1 received ERN/LRPT (1 g) plus the run‐in statin dose and advanced to ERN/LRPT (2 g) after 4 weeks for an additional 8 weeks, with no adjustments to the run‐in statin dose; group 2 received simvastatin or atorvastatin at twice their run‐in statin dose and remained on this stable dose for 12 weeks.
Results: ERN/LRPT added to statin (pooled across statin and statin dose) significantly improved key lipid parameters vs. the doubled statin dose (pooled): the between‐treatment group difference in least squares mean per cent change [95% confidence interval (CI)] from baseline to week 12 in LDL‐C (primary end‐point) was −4.5% (−7.7, −1.3) and in high‐density lipoprotein cholesterol (HDL‐C) was 15.6% (13.4, 17.9) and in median per cent change for triglyceride (TG) was −15.4% (−19.2, −11.7). Treatment‐related adverse experiences (AEs) related to flushing, pruritis, rash, gastrointestinal upset and elevations in liver transaminases and fasting serum glucose occurred more frequently with ERN/LRPT added to statin vs. statin dose doubled.
Conclusions: The addition of ERN/LRPT to ongoing statin treatment produced significantly improved lipid‐modifying benefits on LDL‐C, HDL‐C and TG and all other lipid parameters compared with doubling the statin dose in patients with primary hypercholesterolaemia or mixed dyslipidaemia. The types of AEs that occurred at a greater frequency in the ERN/LRPT group were those typically associated with niacin.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/j.1742-1241.2010.02370.x</identifier><identifier>PMID: 20518948</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject><![CDATA[Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Delayed-Action Preparations - administration & dosage ; Delayed-Action Preparations - adverse effects ; Disorders of blood lipids. Hyperlipoproteinemia ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Combinations ; Dyslipidemias - drug therapy ; Female ; General aspects ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hypercholesterolemia - drug therapy ; Hypolipidemic Agents - administration & dosage ; Hypolipidemic Agents - adverse effects ; Indoles - administration & dosage ; Indoles - adverse effects ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; Niacin - administration & dosage ; Niacin - adverse effects ; Prostaglandin D2 - antagonists & inhibitors ; Treatment Outcome ; Young Adult]]></subject><ispartof>International journal of clinical practice (Esher), 2010-05, Vol.64 (6), p.727-738</ispartof><rights>2010 Blackwell Publishing Ltd</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4870-3c2a4de79c616b0bc80ac73100627a228af4908c3e2eb8bc9c0b6722d261b08e3</citedby><cites>FETCH-LOGICAL-c4870-3c2a4de79c616b0bc80ac73100627a228af4908c3e2eb8bc9c0b6722d261b08e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1742-1241.2010.02370.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1742-1241.2010.02370.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22689117$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20518948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shah, S.</creatorcontrib><creatorcontrib>Ceska, R.</creatorcontrib><creatorcontrib>Gil-Extremera, B.</creatorcontrib><creatorcontrib>Paolini, J. F.</creatorcontrib><creatorcontrib>Giezek, H.</creatorcontrib><creatorcontrib>Vandormael, K.</creatorcontrib><creatorcontrib>Mao, A.</creatorcontrib><creatorcontrib>McCrary Sisk, C.</creatorcontrib><creatorcontrib>Maccubbin, D.</creatorcontrib><title>Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Summary
Background: Co‐administration of niacin with statin offers the potential for additional lipid management and cardiovascular risk reduction. However, niacin is underutilised because of the side effects of flushing, mediated primarily by prostaglandin D2 (PGD2). A combination tablet containing extended‐release niacin and laropiprant (ERN/LRPT), a PGD2 receptor (DP1) antagonist, offers improved tolerability. This study assessed the efficacy and safety of ERN/LRPT added to statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia who were not at their National Cholesterol Education Program Adult Treatment Panel III low‐density lipoprotein cholesterol (LDL‐C) goal based on their coronary heart disease risk category (high, moderate or low).
Methods: After a 2‐ to 6‐week run‐in statin (simvastatin 10 or 20 mg or atorvastatin 10 mg) period, 1216 patients were randomised equally to one of two treatment groups in a double‐blind fashion: group 1 received ERN/LRPT (1 g) plus the run‐in statin dose and advanced to ERN/LRPT (2 g) after 4 weeks for an additional 8 weeks, with no adjustments to the run‐in statin dose; group 2 received simvastatin or atorvastatin at twice their run‐in statin dose and remained on this stable dose for 12 weeks.
Results: ERN/LRPT added to statin (pooled across statin and statin dose) significantly improved key lipid parameters vs. the doubled statin dose (pooled): the between‐treatment group difference in least squares mean per cent change [95% confidence interval (CI)] from baseline to week 12 in LDL‐C (primary end‐point) was −4.5% (−7.7, −1.3) and in high‐density lipoprotein cholesterol (HDL‐C) was 15.6% (13.4, 17.9) and in median per cent change for triglyceride (TG) was −15.4% (−19.2, −11.7). Treatment‐related adverse experiences (AEs) related to flushing, pruritis, rash, gastrointestinal upset and elevations in liver transaminases and fasting serum glucose occurred more frequently with ERN/LRPT added to statin vs. statin dose doubled.
Conclusions: The addition of ERN/LRPT to ongoing statin treatment produced significantly improved lipid‐modifying benefits on LDL‐C, HDL‐C and TG and all other lipid parameters compared with doubling the statin dose in patients with primary hypercholesterolaemia or mixed dyslipidaemia. The types of AEs that occurred at a greater frequency in the ERN/LRPT group were those typically associated with niacin.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Delayed-Action Preparations - administration & dosage</subject><subject>Delayed-Action Preparations - adverse effects</subject><subject>Disorders of blood lipids. Hyperlipoproteinemia</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Dyslipidemias - drug therapy</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>Hypolipidemic Agents - administration & dosage</subject><subject>Hypolipidemic Agents - adverse effects</subject><subject>Indoles - administration & dosage</subject><subject>Indoles - adverse effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Niacin - administration & dosage</subject><subject>Niacin - adverse effects</subject><subject>Prostaglandin D2 - antagonists & inhibitors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUdtu1DAQjRCIlsIvIL8gnpL6ktjOCxJatUtRBRUq4tFynAnrxblgJzT5Jz4Sp7ssr1iWPJ45c-ZykgQRnJF4LvcZETlNCc1JRnH0YsoEzuYnyfkp8DTajMu0wIycJS9C2GNMi0Li58kZxQWRZS7Pk99XTWONNgvSXY2CbmBcUN8gmEfoaqhTDw50ANRZbWx36bTvBzt43Y1ocFNAYdSj7dCvkKG6nypnu-9o3EH8xKRIdIzHO0QDujGgBzvu0OBtq_2CdssA3ux6B2EE3zsNrdWo96i1M9SoXoKzg60f3S-TZ412AV4d34vk6_XV_eZDevt5e7N5f5uaXAqcMkN1XoMoDSe8wpWRWBvBCMacCk2p1E1eYmkYUKhkZUqDKy4orSknFZbALpK3B97B9z-n2JhqbTDgnO6gn4ISjBEW98wjUh6QxvcheGjUcS5FsFqlUnu1KqJWRdQqlXqUSs0x9fWxyFS1UJ8S_2oTAW-OAB2Mdk3cubHhH45yWRIiIu7dAfdgHSz_3YC6-bi5W81IkB4IbJRgPhFo_0NxwUShvn3aKobvt_zLHY_D_wF_J8KC</recordid><startdate>201005</startdate><enddate>201005</enddate><creator>Shah, S.</creator><creator>Ceska, R.</creator><creator>Gil-Extremera, B.</creator><creator>Paolini, J. F.</creator><creator>Giezek, H.</creator><creator>Vandormael, K.</creator><creator>Mao, A.</creator><creator>McCrary Sisk, C.</creator><creator>Maccubbin, D.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201005</creationdate><title>Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia</title><author>Shah, S. ; Ceska, R. ; Gil-Extremera, B. ; Paolini, J. F. ; Giezek, H. ; Vandormael, K. ; Mao, A. ; McCrary Sisk, C. ; Maccubbin, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4870-3c2a4de79c616b0bc80ac73100627a228af4908c3e2eb8bc9c0b6722d261b08e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Delayed-Action Preparations - administration & dosage</topic><topic>Delayed-Action Preparations - adverse effects</topic><topic>Disorders of blood lipids. Hyperlipoproteinemia</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Dyslipidemias - drug therapy</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>Hypolipidemic Agents - administration & dosage</topic><topic>Hypolipidemic Agents - adverse effects</topic><topic>Indoles - administration & dosage</topic><topic>Indoles - adverse effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Niacin - administration & dosage</topic><topic>Niacin - adverse effects</topic><topic>Prostaglandin D2 - antagonists & inhibitors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shah, S.</creatorcontrib><creatorcontrib>Ceska, R.</creatorcontrib><creatorcontrib>Gil-Extremera, B.</creatorcontrib><creatorcontrib>Paolini, J. F.</creatorcontrib><creatorcontrib>Giezek, H.</creatorcontrib><creatorcontrib>Vandormael, K.</creatorcontrib><creatorcontrib>Mao, A.</creatorcontrib><creatorcontrib>McCrary Sisk, C.</creatorcontrib><creatorcontrib>Maccubbin, D.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shah, S.</au><au>Ceska, R.</au><au>Gil-Extremera, B.</au><au>Paolini, J. F.</au><au>Giezek, H.</au><au>Vandormael, K.</au><au>Mao, A.</au><au>McCrary Sisk, C.</au><au>Maccubbin, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2010-05</date><risdate>2010</risdate><volume>64</volume><issue>6</issue><spage>727</spage><epage>738</epage><pages>727-738</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Summary
Background: Co‐administration of niacin with statin offers the potential for additional lipid management and cardiovascular risk reduction. However, niacin is underutilised because of the side effects of flushing, mediated primarily by prostaglandin D2 (PGD2). A combination tablet containing extended‐release niacin and laropiprant (ERN/LRPT), a PGD2 receptor (DP1) antagonist, offers improved tolerability. This study assessed the efficacy and safety of ERN/LRPT added to statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia who were not at their National Cholesterol Education Program Adult Treatment Panel III low‐density lipoprotein cholesterol (LDL‐C) goal based on their coronary heart disease risk category (high, moderate or low).
Methods: After a 2‐ to 6‐week run‐in statin (simvastatin 10 or 20 mg or atorvastatin 10 mg) period, 1216 patients were randomised equally to one of two treatment groups in a double‐blind fashion: group 1 received ERN/LRPT (1 g) plus the run‐in statin dose and advanced to ERN/LRPT (2 g) after 4 weeks for an additional 8 weeks, with no adjustments to the run‐in statin dose; group 2 received simvastatin or atorvastatin at twice their run‐in statin dose and remained on this stable dose for 12 weeks.
Results: ERN/LRPT added to statin (pooled across statin and statin dose) significantly improved key lipid parameters vs. the doubled statin dose (pooled): the between‐treatment group difference in least squares mean per cent change [95% confidence interval (CI)] from baseline to week 12 in LDL‐C (primary end‐point) was −4.5% (−7.7, −1.3) and in high‐density lipoprotein cholesterol (HDL‐C) was 15.6% (13.4, 17.9) and in median per cent change for triglyceride (TG) was −15.4% (−19.2, −11.7). Treatment‐related adverse experiences (AEs) related to flushing, pruritis, rash, gastrointestinal upset and elevations in liver transaminases and fasting serum glucose occurred more frequently with ERN/LRPT added to statin vs. statin dose doubled.
Conclusions: The addition of ERN/LRPT to ongoing statin treatment produced significantly improved lipid‐modifying benefits on LDL‐C, HDL‐C and TG and all other lipid parameters compared with doubling the statin dose in patients with primary hypercholesterolaemia or mixed dyslipidaemia. The types of AEs that occurred at a greater frequency in the ERN/LRPT group were those typically associated with niacin.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20518948</pmid><doi>10.1111/j.1742-1241.2010.02370.x</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2010-05, Vol.64 (6), p.727-738 |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733137426 |
| source | MEDLINE; Wiley Journals |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Cholesterol, HDL - blood Cholesterol, LDL - blood Delayed-Action Preparations - administration & dosage Delayed-Action Preparations - adverse effects Disorders of blood lipids. Hyperlipoproteinemia Dose-Response Relationship, Drug Double-Blind Method Drug Combinations Dyslipidemias - drug therapy Female General aspects Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hypercholesterolemia - drug therapy Hypolipidemic Agents - administration & dosage Hypolipidemic Agents - adverse effects Indoles - administration & dosage Indoles - adverse effects Male Medical sciences Metabolic diseases Middle Aged Niacin - administration & dosage Niacin - adverse effects Prostaglandin D2 - antagonists & inhibitors Treatment Outcome Young Adult |
| title | Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A35%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20extended-release%20niacin/laropiprant%20plus%20statin%20vs.%20doubling%20the%20dose%20of%20statin%20in%20patients%20with%20primary%20hypercholesterolaemia%20or%20mixed%20dyslipidaemia&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Shah,%20S.&rft.date=2010-05&rft.volume=64&rft.issue=6&rft.spage=727&rft.epage=738&rft.pages=727-738&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/j.1742-1241.2010.02370.x&rft_dat=%3Cproquest_cross%3E733137426%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733137426&rft_id=info:pmid/20518948&rfr_iscdi=true |